Friday, November 16 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery and real world evidence pipeline utilizing the next generation artificial intelligence, will present its research and introduce the "Cure a disease in a year" program at the World's leading congress for big data in precision medicine - Biodata World Congress 2018.
Biodata World 2018 is the world's leading conference focused on big data and precision medicine. It brings together new methods in data discovery and generation, applications of AI and machine learning. The congress will take place at Congress Center Basel, 28-29 November 2018.
"Our company published the many proofs of concept for the applications of modern AI in drug discovery and completed many pilots. However, the pharmaceutical industry is not moving fast enough. Several pharmaceutical companies are claiming to have hundreds of data scientists and the many petabytes of legacy data that will help them turn into the data companies. But so far with no tangible results coming out of these efforts. It is time to unveil our end-to-end drug discovery pipeline and offer rare disease foundations a chance to collect the data required for this pipeline and get the targets and molecules for testing. For the first time we will present our "Cure a disease in a year" program at Biodata World Congress 2018, which gathers the key opinion leaders from the academia and industry.", saids Alex Zhavoronkov, PhD, Founder, and CEO of Insilico Medicine, Inc.
"Artificial Intelligence (AI) techniques, such as deep learning (DL), reinforcement learning (RL), and generative adversarial networks (GANs) play a pivotal role in studying the biology of aging on many levels. We are excited to share our vision and latest results at the industry's leading event for Data and AI in healthcare", - said Alex Zhebrak, CTO of Insilico Medicine, Inc.
According to the Chair of "AI in Ageing Research and Longevity" Round Table, Tina Woods, Founder of Collider Health: "This is an exciting time in health and longevity. Insights can be gathered from DNA and other health, behavioral and environmental information with astonishing efficiency using AI- and all this can drive 'smarter' research and more personalized strategies to increase our 'healthspan'. I hope one day we can each have our own 'Life Dashboard' giving us the power to leverage our genetic, health, wealth and life data, and nudging us in the right ways to live a longer, healthier life while helping billions of others too".
BioData World EU 2018
Day 2 - Thursday 29th November 2018 16:20
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
Talk: Cure a disease in a year challenge
Presenter: Alex Zhavoronkov, PhD, CEO and Founder, Insilico Medicine
Round Table F: AI in Ageing Research and Longevity
Presenter: Alex Zhebrak, CTO, Insilico Medicine
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine.
For further information, images or interviews, please contact:
Official website of the conference: https:/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/